

产品名称：帕瑞昔布  
产品别名：Parecoxib

## 生物活性：

Description	<p>Parecoxib is a potent and selective COX-2 inhibitor. IC50 value: Target: COX-2 in vitro: The prodrug Parecoxib as well as its active metabolite val have a specific affinity to the cannabinoid (CB) receptor measured in CB1-expressing HEK 293 cells and rat brain tissue [1]. in vivo: Adult male Sprague-Dawley rats were administered parecoxib (10 or 30 mg kg(-1), IP) or isotonic saline twice a day starting 24 h after middle cerebral artery occlusion (MCAO) for three consecutive days [2]. The selective COX-2 inhibitor parecoxib was delivered 20 min before or 20 min after the incision by intraperitoneal injection. Pretreatment with parecoxib markedly attenuated the pain hypersensitivity induced by incision [3].</p>																	
Solvent&Solubility	<p><b>In Vitro:</b></p> <p><b>DMSO : ≥ 50 mg/mL (134.98 mM)</b></p> <p>* "≥" means soluble, but saturation unknown.</p>																	
	<table><tr><td rowspan="4">Preparing    <b>Stock Solutions</b></td><td><div>Solvent / Mass / Concentration</div></td><td><b>1 mg</b></td><td><b>5 mg</b></td><td><b>10 mg</b></td></tr><tr><td>1 mM</td><td>2.6996 mL</td><td>13.4982 mL</td><td>26.9964 mL</td></tr><tr><td>5 mM</td><td>0.5399 mL</td><td>2.6996 mL</td><td>5.3993 mL</td></tr><tr><td>10 mM</td><td>0.2700 mL</td><td>1.3498 mL</td><td>2.6996 mL</td></tr></table>	Preparing    <b>Stock Solutions</b>	<div>Solvent / Mass / Concentration</div>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>	1 mM	2.6996 mL	13.4982 mL	26.9964 mL	5 mM	0.5399 mL	2.6996 mL	5.3993 mL	10 mM	0.2700 mL	1.3498 mL	2.6996 mL
	Preparing    <b>Stock Solutions</b>		<div>Solvent / Mass / Concentration</div>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>												
			1 mM	2.6996 mL	13.4982 mL	26.9964 mL												
			5 mM	0.5399 mL	2.6996 mL	5.3993 mL												
10 mM		0.2700 mL	1.3498 mL	2.6996 mL														
<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液，一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80℃, 6 months; -20℃, 1 month。 -80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。</p> <p><b>In Vivo:</b></p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 <b>In Vitro</b> 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 2.5 mg/mL (6.75 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (6.75 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2.请依序添加每种溶剂： 10% DMSO →90% corn oil</p> <p>Solubility: ≥ 2.5 mg/mL (6.75 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (6.75 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p>																		
References	<p>[1]. <u>Ye Z, et al. Delayed administration of parecoxib, a specific COX-2 inhibitor, attenuated postischemic neuronal apoptosis by phosphorylation Akt and GSK-3β. Neurochem Res. 2012 Feb;37(2):321-9.</u></p> <p>[2]. <u>Schr?der H, et al. Parecoxib and its metabolite valdecoxib directly interact with cannabinoid binding</u></p>																	

sites in CB1-expressing HEK 293 cells and rat brain tissue. Neurochem Int. 2011 Jan;58(1):9-13.

[3]. Guo YJ, et al. Analgesic effects of the COX-2 inhibitor parecoxib on surgical pain through suppression of spinal ERK signaling. Exp Ther Med. 2013 Jul;6(1):275-279.



源叶生物